Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
India's white-collar job market experienced a 14 per cent year-on-year growth in August, with the auto, healthcare, and retail sectors leading the surge, according to a report by Naukri.com.
Five Raksha Bandhan ads that stayed with us long after the festival was over...
Indian benchmark indices Sensex and Nifty rebounded in early trade after three days of decline, driven by a rally in Sun Pharma following its USD 11.75 billion acquisition of US-based Organon & Co, alongside a positive trend in global equity markets.
'India is vulnerable to the West Asia crisis in three ways: Energy costs, the business Indian companies conduct in the region, and remittances from the Indian diaspora.'
Indian benchmark indices, Sensex and Nifty, continued their downward trend for the fifth consecutive day, with the Sensex dropping 281 points and Nifty falling 78 points, primarily driven by surging crude oil prices and persistent geopolitical tensions in West Asia.
Indian stock markets closed lower due to selling in IT and FMCG shares, triggered by renewed tensions in West Asia which led to a rally in crude oil prices and concerns over inflation and interest rates.
US Ambassador to India, Sergio Gor, highlighted the evolving US-India space partnership, moving from cooperation to "co-creation" at the Bengaluru Space Expo. He emphasised joint design, funding, and co-authoring the future of human discovery, citing the NISAR satellite and India's participation in the Artemis Accords as key examples of this growing synergy.
Indian benchmark indices Sensex and Nifty experienced a significant slump in early trade, mirroring a bearish trend in global equities, as escalating conflict in West Asia drove up crude oil prices and intensified investor concerns.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
In the next 36 months nearly 25 to 40 per cent of jobs will be under threat from AI and job losses are inevitable.
The Maharashtra Food and Drug Administration (FDA) has cancelled the licences of 10 Ayurvedic drug manufacturing units and issued show-cause notices to 135 others following inspections that revealed serious violations including unhygienic conditions, lack of technical staff, and inadequate testing protocols.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
Indian benchmark equity indices, Sensex and Nifty, closed lower for multiple consecutive days, with the Nifty extending its losses to a seventh day, primarily due to elevated crude oil prices following the expiry of the US-Iran ceasefire without a diplomatic resolution.
Indian benchmark indices Sensex and Nifty experienced declines in early trade, driven by a surge in Brent crude oil prices above USD 91 per barrel due to escalating tensions between Iran and the US, alongside an increase in US 10-year bond yields. Track Sensex, Nifty on August 18.
Indian benchmark equity indices, Sensex and Nifty, experienced declines in early trade due to elevated crude oil prices and persistent geopolitical uncertainties, particularly following the expiry of the US-Iran ceasefire. Track Sensex, Nifty on August 19, 2026.
Odisha-based Serendipity Space successfully demonstrated drug crystallisation processes on a satellite prototype in a near-space mission. This breakthrough aims to enable pharmaceutical manufacturing in low Earth orbit, leveraging microgravity to create superior drug crystal structures for enhanced solubility, stability, and effectiveness. The mission tested core technologies, including an autonomous pharmaceutical factory, and was inspired by advancements made on the International Space Station.
India's 10 most valuable families had a combined valuation of Rs 70.5 trillion.
Indian benchmark indices, Sensex and Nifty, experienced declines in early trade due to a surge in crude oil prices and significant selling pressure on bank stocks, impacting overall investor sentiment. Track Sensex, Nifty on July 22.
'Improved law and order and transparent governance have helped change UP's investment image.'
US President Donald Trump announced steep tariffs on imported generic medicines, effective from August 2028, with the aim of boosting domestic pharmaceutical production. This policy, which includes a phased increase in tariffs up to 200 per cent, could significantly impact India, a major global supplier of generic drugs to the US market.
Combine a robust base health plan with a super top-up, critical illness cover and a dedicated medical corpus to protect household finances from soaring treatment costs.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
Indian stock market benchmark indices, Sensex and Nifty, saw significant gains in early trade, driven by a sharp decline in crude oil prices and easing geopolitical tensions, alongside renewed foreign fund inflows.
India's outward foreign direct investment (FDI) plummeted by 47.9 per cent year-on-year to $3 billion in June 2026, according to the Reserve Bank of India (RBI), with declines across equity, debt, and guarantee commitments.
Indian benchmark stock indices, Sensex and Nifty, extended their winning streak to a fourth day, with Nifty surging 1.60 per cent, driven by a sharp decline in crude oil prices and renewed foreign fund inflows.
Indian benchmark indices, Sensex and Nifty, opened in positive territory, primarily driven by a strong performance in IT stocks, sustained foreign fund inflows, and a dip in global crude oil prices, despite a hawkish stance from the US Federal Reserve. Track Sensex, Nifty on July 30.
Indian benchmark indices, Sensex and Nifty, opened higher on Friday, primarily driven by a significant surge in Bajaj Finance shares following its strong Q1 FY27 earnings report, coupled with continued foreign fund inflows and a dip in crude oil prices. Track Sensex, Nifty on July 31.
Indian benchmark equity indices closed higher on Thursday, with the Sensex gaining 273.55 points to 77,928.15 and the Nifty rising 66.95 points to 24,317.15, driven by bargain hunting and short-covering in IT and auto sectors.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, driven by renewed tensions between the US and Iran and a subsequent spike in global crude oil prices, creating uncertainty in the market. Track Sensex, Nifty on July 8.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
Homegrown pharma major Cipla Ltd reported a 39 per cent decline in consolidated net profit to Rs 785.55 crore in the first quarter ended June 2026, primarily due to a dip in sales in the North American market and higher expenses.
The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, with the Sensex falling over 500 points and the Nifty over 150 points, as Brent crude oil prices surged past USD 100 per barrel due to escalating geopolitical tensions in the West Asia. track sensex, Nifty on July 24.
Indian benchmark indices Sensex and Nifty rebounded in early trade on Thursday, recovering from a sharp fall in the previous session, driven by foreign fund inflows and buying in key blue-chip stocks. Track Sensex, Nifty on July 9, 2026.
Congress MP from Jalandhar, Charanjit Singh Channi, was conspicuous by his absence when party leader Rahul Gandhi spoke in a debate in the Lok Sabha on Wednesday, bringing to the fore the recent rift within the party's state unit.
Indian benchmark indices Sensex and Nifty rallied in early trade, primarily driven by strong buying in IT stocks after Tech Mahindra reported a significant 28.4 per cent rise in its consolidated net profit for the June quarter.
Indian benchmark indices Sensex and Nifty experienced a downturn in early trade, primarily influenced by a dip in HDFC Bank shares, persistent outflows from foreign funds, and escalating geopolitical tensions between the US and Iran. Track Sensex, Nifty performance.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
